"I think it is the most meaningful because it's not a jury of our peers or a popularity contest," says Alan Topin, president of Topin & Associates, whose agency stole the show, winning three awards for its four-page Dusa ClindaReach (Clindamycin) launch ad for acne. "[These awards] deal with ethics—so in that sense we are triply delighted with our work."
For Robin Shapiro, senior vice president and executive creative director at Corbett Worldwide Healthcare Communications, the Doctors' Choice Awards takes the temperature of an idea's ability to break through the competitive clutter. "The fact that physicians choose the winners makes this show a favorite of many clients," she says.Find the Winning Formula
Reflecting the broader trend in drug development, an ad took first place in two categories for two different indications for the first time this year. That campaign—produced by GSW Worldwide for Lilly's Cymbalta (duloxetine)—struck a chord with physicians specializing in gastroenterology and neurology.
Dean Tepper, senior vice president and group creative director of GSW, says that there are two reasons why the Cymbalta ads "communicated the brand's benefits in a compelling way": the target patient is clearly identified through the casting, and the use of four successive single page ads offer a chance to tell the brand's story. "It helped communicate the various problems patients face while also showing the resolution," says Tepper.
Corbett took home two awards at the event, one for the "pink eye" treatment Vigamox (moxifloxacin), which doctors said had immediate appeal—and which Shapiro said was steeped in solid branding principles: "Our goal is to go beyond the campaign idea to build proprietary brand identities. The Vigamox work is an example of both instant communication and a proprietary brand identity."
Shapiro also mentions that today's pharma promotion has to do a better job of communicating information, rather than just selling product. "Physicians are looking to reclaim control over their lives," he says. "They are less receptive to sales calls, and increasingly look to receive information on their own time and their own terms."
According to David Paragamian, president of Euro RSCG Life LM&P, even for professional marketers, it is more important than ever to look beyond what was once considered "narrow" communication. "We believe that communication that works is integrated across target audiences, connecting the healthcare professional, the patient, in some therapeutic areas the loved ones, and, of course, payers," he says. "It's also integrated across communication channels, such as print and online."
As for next year's event, William Castagnoli, director of the Doctors' Choice Awards, advises pharmaceutical and biotech companies to step out of the shadow of me-too drugs and hew to the basics. "I would urge advertisers to look for new information you can deliver. Then dress it up. Why would a doctor look through a journal when he has a lot of other things to do? He is looking to learn something new," Castagnoli says. "The wining formula is to deliver information clearly, and then create a graphic that directs attention."
Brittany Agro is Pharmaceutical Executive's assistant editor. She can be reached at firstname.lastname@example.org